前列腺特异性膜抗原正电子发射断层扫描检测的疾病范围与高危非转移性去势抵抗性前列腺癌患者的总生存期:一项国际多中心回顾性研究
本研究对200例经传统影像学未发现转移的高危非转移性去势抵抗性前列腺癌(nmCRPC)患者行PSMA-PET,中位随访43个月,评估PSMA-PET所示疾病范围与结局的关系。多转移性疾病(PET上≥5个远处病灶)与较短的总生存期(中位61个月 vs 未达到;HR 1.81,95%CI 1.00-3.27;p=0.050)和至新发转移时间(中位38 vs 60个月;HR 1.80,95%CI 1.10-2.96;p=0.019)独立相关,初始pN1状态与较短的总生存期相关(55个月 vs 未达到;HR 1.94,95%CI 1.12-3.37;p=0.019)。
要点
- PSMA-PET可在传统影像学判为无远处转移的高危nmCRPC患者中检出远处转移。
- 多转移性疾病(≥5个远处病灶)与较短的总生存期和至新发转移时间独立相关。
- 初始pN1状态与较短的总生存期独立相关。
核心结论
- PSMA-PET可为nmCRPC患者提供额外的风险分层。
- 多转移性疾病(≥5个远处病灶)与更差的结局相关。
研究设计与样本
- 国际多中心回顾性研究,对200例经传统影像学无转移的高危nmCRPC患者行PSMA-PET后随访,中位随访43个月。
- 采用Kaplan-Meier模型和Cox多变量回归分析患者特征、PSMA-PET表现、治疗管理与结局之间的关联。
主要发现
- PSMA-PET在109/200例(39%远处淋巴结、24%骨、6%内脏器官)中检出远处转移。
- 多转移性疾病(PET上≥5个远处病灶)与较短的总生存期独立相关(中位61个月 vs 未达到;HR 1.81,95%CI 1.00-3.27;p=0.050)。
- 多转移性疾病与较短的至新发转移时间独立相关(中位38 vs 60个月;HR 1.80,95%CI 1.10-2.96;p=0.019)。
- 初始pN1状态与较短的总生存期独立相关(55个月 vs 未达到;HR 1.94,95%CI 1.12-3.37;p=0.019)。
- PSMA-PET后,无/局部病变者最常用局部挽救治疗(58%),远处转移性疾病者最常用雄激素受体信号抑制剂(51%)。
临床怎么用
- PSMA-PET可为nmCRPC患者提供额外的风险分层。
- 多转移性疾病(≥5个远处病灶)与更差的结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previously, we demonstrated that prostate-specific membrane antigen positron emission tomography (PSMA-PET) revealed distant metastases in 109/200 patients (39% distant nodes, 24% bone, and 6% visceral organ) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and high-risk features (International Society of Urological Pathology score ≥4 and/or prostate-specific antigen doubling time ≤10 mo) without metastases by conventional imaging. However, the impact of disease extent determined by PSMA-PET on patient outcomes is unknown. We followed these 200 patients for a median of 43 mo after PSMA-PET and retrospectively assessed the association between patient characteristics, PSMA-PET findings, treatment management, and outcomes using a Kaplan-Meier model and Cox multivariable regressions. Among assessed disease characteristics, polymetastatic disease (five or more distant lesions on PET) was independently associated with shorter overall survival (OS; median 61 mo vs not reached; hazard ratio [95% confidence interval], 1.81 [1.00-3.27]; p = 0.050) and time to new metastases (median 38 vs 60 mo; 1.80 [1.10-2.96]; p = 0.019), and initial pN1 status with shorter OS (55 mo vs not reached; 1.94 [1.12-3.37]; p = 0.019). Following PSMA-PET, locoregional salvage therapies were used most commonly in no/local disease (58%), and androgen receptor signaling inhibitors were used in distant metastatic disease (51%). PSMA-PET provides additional risk stratification for patients with nmCRPC. Polymetastatic disease (five or more distant lesions) is associated with worse outcomes. PATIENT SUMMARY: A novel sensitive imaging technology, called prostate-specific membrane antigen positron emission tomography (PSMA-PET), allows doctors to detect the spread of prostate cancer, known as distant metastases, earlier and more accurately than in the past. In our study, PSMA-PET detected none to many metastases in patients who were considered free of distant metastasis by conventional imaging. These findings predicted outcomes and were used to select appropriate treatment.
引用
- Weber M, Fendler WP, Ravi Kumar AS, et al. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Eur Urol. 2024. PMID: 38490855. doi:10.1016/j.eururo.2024.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。